retatrutide phase 2 trial type 2 diabetes results 2024 💉 may be redefining obesity treatment. New data from TRIUMPH-1 showed: 🔥 ~28% average weight loss over 80 weeks 🔥 >30% weight loss in nearly half of participant #ObesityMedicine #Retatrutide #GLP1 #CardioMetabolic Weight loss with retatrutide as

LAMs differ from other macrophage subtypes by their high lysosomal and phagocytotic activity, thereby preserving tissue integrity under metabolically demanding conditions 29

One way to interpret this figure is to select a change in body weight of interest on the horizontal axis and note the corresponding proportions of patients (vertical axis) in each treatment group who achieved at least that degree of weight loss

doi: 10.3390/nu12092573 12

HFD-fed obese mice responded to p.o

Key parameters included IR (measured using HOMA-IR), metabolic gene expression (quantified via RT-PCR), and fatty acid composition (analyzed by gas chromatography)